Detalhe da pesquisa
1.
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Oncologist
; 2024 Feb 23.
Artigo
Inglês
| MEDLINE | ID: mdl-38394384
2.
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 384(9): 829-841, 2021 03 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33657295
3.
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Cancer
; 126(18): 4156-4167, 2020 09 15.
Artigo
Inglês
| MEDLINE | ID: mdl-32673417
4.
Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study.
JCO Glob Oncol
; 8: e2100276, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-35324270
5.
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.
Eur Urol
; 72(3): 368-376, 2017 09.
Artigo
Inglês
| MEDLINE | ID: mdl-28410865
6.
Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer.
Lung Cancer
; 38(3): 309-15, 2002 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-12445754
7.
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.
Invest New Drugs
; 21(4): 435-43, 2003 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-14586211